Panobinostat phase 1 trial provides limited advance in HDAC inhibitor pipeline
The first clinical trial of Panobinostat by the Department of Infectious Diseases and Department of Immunology at Aarhus University Hospital, Denmark marks the next step in the development of the histone deactylase (HDAC) inhibitor group of latency reversal agents [1]. Thomas Rasmussen and colleagues describe results from this single-arm phase1/2 clinical trial of the second …
Panobinostat phase 1 trial provides limited advance in HDAC inhibitor pipeline Read More »